ThermoGenesis Holdings, Inc., a California-based company that develops and commercializes automated technologies for cell-based therapies, is making strides in the emerging chimeric antigen receptor (CAR-T) market. The company's semi-automated CAR-TXpress platform streamlines the manufacturing process for CAR-T immunotherapy, while its suite of solutions includes automated clinical biobanking and point-of-care applications for immuno-oncology. ThermoGenesis Holdings also provides several automated systems for cellular processing, including cell separation, washing, and purification. The company's X-Series products target varying cell isolation needs, while the CAR-TXpress Platform specifically addresses the large scale cellular processing and chemistry, manufacturing, and controls needs of this growing market. ThermoGenesis Holdings, Inc. was formerly known as Cesca Therapeutics Inc. and changed its name in November 2019.